Endo to Acquire Par Pharmaceutical
Woodcliff, NJ - Endo International plc and Woodcliff Lakes-based Par Pharmaceutical Holdings, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest growing and among the top five as measured by U.S. sales. It is also expected to help drive long-term double-digit revenue growth for Endo.
What a Venture Capitalist Wants
Trenton, NJ – We know what businesses are looking for capital investments when they go to a venture capital firm, but what are venture capitalists looking for from them? What qualities will help them decide to invest in a business? Richard Harroch wrote an article titled, “12 Venture Capitalists Share How Startups Get Their Attention,” summarizing what twelve venture capitalists have to say about lesson learned, investing in companies like Skype, Uber and Tesla Motors.
Summit, NJ – The Celgene Corporation and San Diego-based Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, announce a definitive share purchase agreement under which Celgene Corporation will acquire Quanticel. Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
Do not miss a single innovative moment and sign up for our newsletter!